Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls

Next Previous
X
Search
Trial Profile

An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Navidea Biopharmaceuticals

    • Most Recent Events

    • 08 Aug 2019 According to a Navidea Biopharmaceuticals media release. results from the study were presented at he Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2019.
    • 17 Jun 2019 Results published in the Navidea Biopharmaceuticals Media Release
    • 02 Apr 2019 According to a Navidea Biopharmaceuticals, data from this study will be presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in June 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top